<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2025-13-4-25-30</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-1107</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Мочеточниковый стент и временная нетрудоспособность</article-title><trans-title-group xml:lang="en"><trans-title>Ureteral stent and temporary disability</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5755-5950</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамаев</surname><given-names>И. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamaev</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ибрагим Энверович Мамаев – канд. мед. наук</p><p>Москва</p></bio><bio xml:lang="en"><p>Ibragim E. Mamaev – Cand.Sc.(Med)</p><p>Moscow</p></bio><email xlink:type="simple">dr.mamaev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9130-148X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сайпулаев</surname><given-names>Г. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Saypulaev</surname><given-names>G. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гаджимурад Шамильевич Сайпулаев</p><p>Москва</p></bio><bio xml:lang="en"><p>Gadzhimurad Sh. Saipulaev</p><p>Moscow</p></bio><email xlink:type="simple">dr.saipulaev@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7957-6421</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Доломанов</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolomanov</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирилл Андреевич Доломанов</p><p>Москва</p></bio><bio xml:lang="en"><p>Kirill A. Dolomanov</p><p>Moscow</p></bio><email xlink:type="simple">dr@kdolomanov.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1989-3254</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глинин</surname><given-names>К. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Glinin</surname><given-names>K. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирилл Игоревич Глинин</p><p>Москва</p></bio><bio xml:lang="en"><p>Kirill I. Glinin</p><p>Moscow</p></bio><email xlink:type="simple">glinin.doc@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Владиславович Котов – д-р мед. наук, профессор</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey V. Kotov – Dr.Sc.(Med), Full Prof.</p><p>Moscow</p></bio><email xlink:type="simple">urokotov@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет им. Н. И. Пирогова; Городская клиническая больница им. В. М. Буянова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University (Pirogov Medical University); Buyanov Moscow City Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница им. В. М. Буянова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Buyanov Moscow City Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет им. Н. И. Пирогова; Городская клиническая больница № 1 им. Н. И. Пирогова; Московский многопрофильный клинический центр «Коммунарка»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University (Pirogov Medical University); «Kommunarka» Moscow Multidisciplinary Clinical Centre; Pirogov City Clinical Hospital № 1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>11</month><year>2025</year></pub-date><volume>13</volume><issue>4</issue><fpage>25</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мамаев И.Э., Сайпулаев Г.Ш., Доломанов К.А., Глинин К.И., Котов С.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мамаев И.Э., Сайпулаев Г.Ш., Доломанов К.А., Глинин К.И., Котов С.В.</copyright-holder><copyright-holder xml:lang="en">Mamaev I.E., Saypulaev G.S., Dolomanov K.A., Glinin K.I., Kotov S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/1107">https://www.urovest.ru/jour/article/view/1107</self-uri><abstract><sec><title>Введение</title><p>Введение. Дренирование верхних мочевых путей временным внутренним мочеточниковым стентом у многих пациентов сопровождается значимой стент-ассоциированной симптоматикой и является ключевым фактором нетрудоспособности на период нахождения стента.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Оценить временную нетрудоспособность пациентов с внутренним мочеточниковым стентом. Провести сопоставление клинической симптоматики, а также субъективных оценок пациентов о своей трудоспособности с фактом выдачи листков нетрудоспособности в рамках характера трудовой деятельности.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 134 официально трудоустроенных пациента, у которых длительность стентирования верхних мочевых путей не превышала двух месяцев. Пациентов просили ответить на пять вопросов, касающихся оценки самочувствия и трудоспособности во время установки стента. Получить ответы на заданные вопросы удалось у всех опрошенных.</p></sec><sec><title>Результаты</title><p>Результаты. Стент-ассоциированные симптомы имело 76,1% пациентов. Нетрудоспособными на протяжении всего времени дренирования верхних мочевых путей оставалось 61,9%, при этом у четверти (25,3%) пациентов, пребывавших в статусе нетрудоспособности, отсутствовали какие-либо симптомы, связанные с наличием стента. Более половины (64,9%) всех пациентов чувствовало себя трудоспособными, а доля пациентов, имевших официальный отвод от трудовой деятельности, связанной с физической активностью, превышала таковую при умственной занятости (59,3% против 45,3%).</p></sec><sec><title>Заключение</title><p>Заключение. Дренирование внутренним стентом в большинстве случаев является поводом для того, чтобы пациент получил статус временно нетрудоспособного. При принятии решения о временной нетрудоспособности врачу следует опираться на следующие параметры: наличие локальной симптоматики, характер трудовой деятельности и субъективная оценка пациентом своего состояния.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Drainage of the upper urinary tract using a temporary internal ureteral stent is frequently associated with significant stent-related symptomatology in many patients and constitutes a major contributor to functional impairment during the stent indwelling period.</p></sec><sec><title>Objective</title><p>Objective. To evaluate temporary disability in patients with ureteral stent. To compare clinical symptoms, the nature of work, the patient’s subjective assessment of his ability to work, medical and social confirmation of the temporary disability.</p></sec><sec><title>Materials &amp; methods</title><p>Materials &amp; methods. The study included 134 officially employed patients whose duration of upper urinary tract stenting did not exceed two months. Patients were asked to respond to five questions regarding their assessment of well-being and work capacity during the stent indwelling period. Responses to the questions were obtained from all respondents.</p></sec><sec><title>Results</title><p>Results. Stent-associated symptomatology was observed in 76.1% of patients. Throughout the entire duration of upper urinary tract drainage, 61.9% of patients remained functionally incapacitated. Notably, 25.3% of those classified as incapacitated were asymptomatic with respect to the presence of the stent. Conversely, 64.9% of all patients reported preserved work capacity. The proportion of patients formally exempted from physically demanding occupational activities exceeded that of those excused from mentally demanding work (59.3% vs 45.3%, respectively).</p></sec><sec><title>Conclusions</title><p>Conclusions. Drainage with an internal stent in most cases justifies assigning the patient a temporary disability status. When determining temporary incapacity for work, the physician should base their decision on the following parameters: presence of local symptomatology, nature of the patient's occupational activity, and the patient's subjective assessment of their condition.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мочеточниковый стент</kwd><kwd>стент-ассоциированная симптоматика</kwd><kwd>временная нетрудоспособность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ureteral stent</kwd><kwd>stent-related symptoms</kwd><kwd>temporary disability</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tolley D. Ureteric stents, far from ideal. Lancet. 2000;356(9233):872-873. DOI: 10.1016/S0140-6736(00)02674-X</mixed-citation><mixed-citation xml:lang="en">Tolley D. Ureteric stents, far from ideal. Lancet. 2000;356(9233):872-873. DOI: 10.1016/S0140-6736(00)02674-X</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Saltzman B. Ureteral stents. Indications, variations, and complications. Urol Clin North Am. 1988;15(3):481-491. PMID: 3043868</mixed-citation><mixed-citation xml:lang="en">Saltzman B. Ureteral stents. Indications, variations, and complications. Urol Clin North Am. 1988;15(3):481-491. PMID: 3043868</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Joshi H.B., Stainthorpe A., MacDonagh R.P., Keeley F.X. Jr, Timoney A.G., Barry M.J. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065-1069; discussion 1069. DOI: 10.1097/01.ju.0000048980.33855.90</mixed-citation><mixed-citation xml:lang="en">Joshi H.B., Stainthorpe A., MacDonagh R.P., Keeley F.X. Jr, Timoney A.G., Barry M.J. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065-1069; discussion 1069. DOI: 10.1097/01.ju.0000048980.33855.90</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shah M., Pillai .S, Chawla A., de la Rosette J.J.M.C.H., Laguna P., Jayadeva Reddy S., Taori R., Hegde P., Mummalaneni S. A randomized trial investigating clinical outcomes and stent-related symptoms after placement of a complete intra-ureteric stent on a string versus conventional stent placement. BJU Int. 2022;129(3):373-379. DOI: 10.1111/bju.15540</mixed-citation><mixed-citation xml:lang="en">Shah M., Pillai .S, Chawla A., de la Rosette J.J.M.C.H., Laguna P., Jayadeva Reddy S., Taori R., Hegde P., Mummalaneni S. A randomized trial investigating clinical outcomes and stent-related symptoms after placement of a complete intra-ureteric stent on a string versus conventional stent placement. BJU Int. 2022;129(3):373-379. DOI: 10.1111/bju.15540</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Contreras P., Frascheri M.F., Bonanno N., Butori S., Blas L., Ameri C. MP65-02 Stent syndrome. Does the diameter matter? Results of a prospective trial. J Urol. 2021;206(Supplement 3):e1119. DOI:10.1097/JU.0000000000002105.02</mixed-citation><mixed-citation xml:lang="en">Contreras P., Frascheri M.F., Bonanno N., Butori S., Blas L., Ameri C. MP65-02 Stent syndrome. Does the diameter matter? Results of a prospective trial. J Urol. 2021;206(Supplement 3):e1119. DOI:10.1097/JU.0000000000002105.02</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Davenport K., Kumar V., Collins J., Melotti R., Timoney A.G., Keeley F.X. Jr. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J Urol. 2011;185(1):175-178. DOI: 10.1016/j.juro.2010.08.089</mixed-citation><mixed-citation xml:lang="en">Davenport K., Kumar V., Collins J., Melotti R., Timoney A.G., Keeley F.X. Jr. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J Urol. 2011;185(1):175-178. DOI: 10.1016/j.juro.2010.08.089</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Krambeck A.E., Walsh R.S., Denstedt J.D., Preminger G.M., Li J., Evans J.C., Lingeman J.E. Lexington Trial Study Group. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol. 2010;183(3):1037-1042. DOI: 10.1016/j.juro.2009.11.035</mixed-citation><mixed-citation xml:lang="en">Krambeck A.E., Walsh R.S., Denstedt J.D., Preminger G.M., Li J., Evans J.C., Lingeman J.E. Lexington Trial Study Group. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol. 2010;183(3):1037-1042. DOI: 10.1016/j.juro.2009.11.035</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta M., Patel T., Xavier K., Maruffo F., Lehman D., Walsh R., Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183(2):598-602. DOI: 10.1016/j.juro.2009.10.021</mixed-citation><mixed-citation xml:lang="en">Gupta M., Patel T., Xavier K., Maruffo F., Lehman D., Walsh R., Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183(2):598-602. DOI: 10.1016/j.juro.2009.10.021</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pecoraro A., Peretti D., Tian Z., Aimar R., Niculescu G., Alleva G., Piana A., Granato S., Sica M., Amparore D., Checcucci E., Manfredi M., Karakiewicz P., Fiori C., Porpiglia F. Treatment of Ureteral Stent-Related Symptoms. Urol Int. 2023;107(3):288-303. DOI: 10.1159/000518387</mixed-citation><mixed-citation xml:lang="en">Pecoraro A., Peretti D., Tian Z., Aimar R., Niculescu G., Alleva G., Piana A., Granato S., Sica M., Amparore D., Checcucci E., Manfredi M., Karakiewicz P., Fiori C., Porpiglia F. Treatment of Ureteral Stent-Related Symptoms. Urol Int. 2023;107(3):288-303. DOI: 10.1159/000518387</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yakoubi R., Lemdani M., Monga M., Villers A., Koenig P. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011;186(3):928-934. DOI: 10.1016/j.juro.2011.04.061</mixed-citation><mixed-citation xml:lang="en">Yakoubi R., Lemdani M., Monga M., Villers A., Koenig P. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011;186(3):928-934. DOI: 10.1016/j.juro.2011.04.061</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bhattar R., Tomar V., Yadav S.S., Dhakad D.S. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent-related lower urinary system symptoms: A prospective randomized trial. Turk J Urol. 2018;44(3):228-238. DOI: 10.5152/tud.2018.50328</mixed-citation><mixed-citation xml:lang="en">Bhattar R., Tomar V., Yadav S.S., Dhakad D.S. Comparison of safety and efficacy of silodosin, solifenacin, tadalafil and their combinations in the treatment of double-J stent-related lower urinary system symptoms: A prospective randomized trial. Turk J Urol. 2018;44(3):228-238. DOI: 10.5152/tud.2018.50328</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
